'schizophrenia' 'psychosis'
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: -Men and women -Mini Mental State score >27 -Written informed consent of the subject;Specific for patients with psychotic symptoms: - Presence of schizophrenic and psychotic symptoms according to DSM-IV criteria using the Comprehensive Assessment of Symptoms and History interview (CASH) (N.B. Official DSM-IV diagnosis can be performed six months after onset of symptoms.)
Exclusion criteria
Exclusion criteria: Healthy controls: -History of psychiatric or neurological illness based (DSM-IV criteria) -First-degree relatives with a family history of schizophrenia or schizophrenia spectrum disorders -Any neurological disorder -(History of) Alcohol and/or drug abuse (DSM-IV criteria) -Any clinical significant abnormality of any clinical laboratory test, including drug screening (but positive cannabis test is allowed for patients) -Any condition that may interfere with MRI scanning, e.g. metal objects in or around the body or claustrophobia -Pregnancy;Specific for medicated patients with psychotic symptoms: - Any neurological disorder;Specific for first episode medication-naive patients with psychotic symptoms: - Use of antipsychotics - Treating physician does not support a delay of medication for the patient (from a clinical perspective) - Risk that the patient causes serious harm to oneself or others - Clinical Global Impressions Severity (CGI-S) score 5 or higher - Psychotic symptoms are too severe to participate (based on CGI-S score and clinical view of treating physician)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the difference in [11C]-R-PK11195 binding potential (BPND) in various brain regions between subjects with psychosis and healthy controls. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome is the relation between microglial activation and other markers for neuronal damage and inflammation. This includes grey matter loss, white matter damage and loss of functional connectivity between brain regions, as well as inflammatory cytokine concentrations in serum. | — |
Countries
Netherlands
Outcome results
None listed